New Data Confirms Early Implantation of Impella 2.5 Prior to PCI Biotech Improves Survival in Shock Patients
11/11/2011 6:27:37 AM
More...
|
Main Results of the Full Phase I/II Study of PCI Biotech's Amphinex(R)
6/27/2011 9:55:53 AM
More...
|
PCI Biotech: Main Results of the Full Phase I/II study of Amphinex(R)
6/24/2011 9:36:34 AM
More...
|
PCI Biotech Announces Last Patient Included in the Phase I/II Study of PC-A11
2/23/2011 7:49:12 AM
More...
|
PCI Biotech Raises NOK90 Million in Rights Issue
6/10/2010 6:39:26 AM
More...
|
PCI Biotech Reports Successful Completion of the Third Dose Group in the Phase I/II Amphinex(R) Trial
3/16/2010 9:52:58 AM
More...
|
PCI Biotech Reports Successful Completion of Second Dose Group in Pivotal Amphinex(R) Trial
1/19/2010 10:07:50 AM
More...
|
PCI Biotech Commences Phase I/II Trials of Amphinex(R) Light-Mediated Therapy Aims to Overcome Both Tumour Cell Uptake Barriers and Toxicity Problems
8/24/2009 8:04:30 AM
More...
|
PCI Biotech: Anti-Tumour Drug More Potent With Light-Directed Delivery
8/19/2009 7:55:35 AM
More...
|
PCI Biotech’s Photochemical Technology Shows Clinical Potential In Mouse Models
7/13/2009 1:13:14 PM
More...
|
|